Overview

The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19

Status:
Not yet recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world.There is no specific drug treatment for this disease. This study is planned to observe the efficacy and safety of Huaier granule in the adjuvant treatment COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tongji Hospital